Literature DB >> 6041727

Re-evaluation of methotrexate as an anticancer drug.

R D Sullivan, E Miller, W Z Zurek, R A Oberfield, Y Ojima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 6041727

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN： 0039-6087


× No keyword cloud information.
  5 in total

Review 1.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

2.  High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results.

Authors:  R B Jones; C E Myers; A M Guarino; R L Dedrick; S M Hubbard; V T DeVita
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 3.  Chemotherapy in colorectal cancer.

Authors:  T J McElwain
Journal:  Proc R Soc Med       Date:  1973-12

4.  The staging and treatment of epithelial ovarian cancer.

Authors:  R C Young; R I Fisher
Journal:  Can Med Assoc J       Date:  1978-08-12       Impact factor: 8.262

5.  Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.

Authors:  A B Miller; D J Klaassen; D A Boyes; D J Dodds; A Gerulath; M E Kirk; M Levitt; J G Pearson; C Wall
Journal:  Can Med Assoc J       Date:  1980-09-06       Impact factor: 8.262
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.